BIGBEAR
PHARMACEUTICAL
Binimetinib is a targeted anti-cancer drug that works by blocking the MEK protein (a key protein that stimulates cancer cell growth) within cancer cells, thereby inhibiting tumor growth.
AuthenticGuaranteeFast DeliveryPrivacy Mechanism of Action of Binimetinib1. Binimetinib is a reversible inhibitor of MEK1 and MEK2 activation.2. MEK proteins are upstream regulators of the ···【More】
Update: 29 Jul,2026Source: BigbearViews: 155
Summary of Drug Interactions for Binimetinib1. Drugs metabolized by hepatic microsomal enzymes: CYP3A4 substrates: No pharmacokinetic interactions hav···【More】
Update: 29 Jul,2026Source: BigbearViews: 197
Binimetinib Special Population Precautions1. PregnancyMay cause fetal harm.2. LactationIt is unknown whether binimetinib or its metabolites are excret···【More】
Update: 28 Jul,2026Source: BigbearViews: 149
Binimetinib is an antineoplastic agent that inhibits mitogen-activated extracellular signal-regulated kinases MEK1 and MEK2.Binimetinib Precautions1. ···【More】
Update: 24 Jul,2026Source: BigbearViews: 178
During treatment with Binimetinib, different side effects may occur. If you have limited knowledge about the side effects of Binimetinib, please consu···【More】
Update: 24 Jul,2026Source: BigbearViews: 219
Dose Adjustments for Specific Adverse Reactions of Binimetinib1. Cardiomyopathy(1) Asymptomatic decrease in left ventricular ejection fraction (LVEF) ···【More】
Update: 24 Jul,2026Source: BigbearViews: 158
Binimetinib usual dose is 45 mg twice daily. Binimetinib is used in combination with Encorafenib for metastatic melanoma and non-small cell lung cance···【More】
Update: 24 Jul,2026Source: BigbearViews: 218
On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination regimen of Binimetinib and Encorafenib for the treatment of pat···【More】
Update: 12 May,2026Source: BigbearViews: 246
October 12, 2023 – New York – (Business Wire)Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi®···【More】
Update: 12 May,2026Source: BigbearViews: 212
Binimetinib is indicated for use in combination with encorafenib for the treatment of advanced melanoma and non-small cell lung cancer (NSCLC) harbori···【More】
Update: 12 May,2026Source: BigbearViews: 198
In June 2018, the U.S. Food and Drug Administration (FDA) approved binimetinib for marketing as a treatment for unresectable metastatic melanoma or me···【More】
Update: 05 Mar,2026Source: BigbearViews: 200
Binimetinib, developed by Pierre Fabre in France, was approved by the U.S. Food and Drug Administration (FDA) in 2018, providing a new treatment optio···【More】
Update: 04 Mar,2026Source: BigbearViews: 194
Binimetinib is often used in combination with encorafenib. These two drugs target the same signaling pathway at different points and can synergistical···【More】
Update: 04 Mar,2026Source: BigbearViews: 186
While binimetinib offers a new treatment option for melanoma patients, its potential adverse reactions still require careful monitoring during use.Sid···【More】
Update: 04 Mar,2026Source: BigbearViews: 190
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
